Scientists have used an AI tool to identify which animals are most likely to contract and spread mutated versions of Covid-19. The model highlighted both pets and wild animals as likely reservoirs for the virus.
Using information about their habitats and various biological traits, researchers at the Cary Institute of Ecosystem Studies in New York developed the machine learning tool to figure out which animals had the particular ACE2 protein that the coronavirus was most likely to latch onto.
Out of 5,400 tested, the scientists narrowed it down to 540 mammalian species.
Some of its predictions have been previously documented as transmission risks, for instance, dogs, cats and bats, while farm animals like pigs and exotic zoo animals were surprise additions.
Other expected additions are minks, Sunda pangolins, and 35 species of bats – which are together ranked among the top 10% of animals most likely to spread the virus, in line with lab results.
The study, published in the Proceedings of the Royal Society journal, also ranked water buffalo, a number of primates, including gorillas and 76 rodent species as being more susceptible to infection.
The researchers taught the AI to identify patterns between rates of transmission and some 60 ecological and biological traits collected by earlier studies, including the overlap between the animal and human habitats as well as their respective lifespans, diets, and sizes.
Previously, the specific amino acid sequences had only been mapped out in around 300 species, including about 143 mammals — and figuring out which ones are more prone to infection is key to predicting the spread of the virus, researchers said.
Arinjay Banerjee at the University of Saskatchewan in Canada told the New Scientist that the results will help researchers “track viral infections and the possible emergence of animal-adapted coronavirus variants” around the world. Barbara Han, who led the study, said predictions needed to be followed up with systematic surveillance and lab studies.
Think your friends would be interested? Share this story!
AstraZeneca has announced that its preventative antibody cocktail offers 83% protection against symptomatic Covid-19 for at least six months, making it more effective than its own vaccine.
In a statement on Thursday, AstraZeneca cemented its lead in the race to develop and market a preventative Covid-19 drug, which is delivered as a shot in the arm.
The drug, named AZD7442, reduces the risk of symptomatic Covid-19 by 83% over the course of six months, according to data from a trial in which participants were given one 300mg dose. There were no deaths or severe infections recorded within the trial group, it said.
A separate trial showed the drug reduced the risk of severe Covid-19 or death by 88% when administered within three days of the onset of symptoms.
“These new data add to the growing body of evidence supporting AZD7442’s potential … We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 [Covid-19] as quickly as possible,” AstraZeneca Executive Vice President Mene Pangalos said in the statement.
The Anglo-Swedish firm has agreed to supply the US government with 700,000 doses of AZD7442 if the Food and Drug Administration grants it emergency use, which AstraZeneca requested on October 5. The firm has similar agreements with other nations.
The drug is created using a combination of two antibodies originating from immune B-cells donated by a recovering Covid-19 patient.
The treatment could be used in people who are known not to respond well to vaccines, such as cancer patients. Around 2% of people are considered to be at risk of not creating enough antibodies following the administration of a Covid-19 vaccine.
Based on the numbers, the drug appears to be more effective than the firm’s first-generation Covid-19 vaccine. Britain’s Zoe Covid study showed the effectiveness of the vaccine dropped to around 67% after four to five months.
